Andreas Diacon
TASK Applied Science Clinical Research Centre · TASK Clinical Research Centre (TCRC) · Karl Bremer Hospital, Cape Town South Africa
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andreas Diacon as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:38 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04044001 · BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)Michael Hoelscher · completed · Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis · principal investigator
- Ph1/Ph2NCT03678688 · A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary TuberculosisOtsuka Pharmaceutical Development & Commercialization, Inc. · completed · Pulmonary TB · principal investigator
- Ph2NCT01691534 · Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)Global Alliance for TB Drug Development · completed · Pulmonary Tuberculosis · principal investigator
- Ph3NCT01642888 · A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSIStatens Serum Institut · completed · Tuberculosis · principal investigator
- Ph2NCT01589497 · Essentiality of INH in TB TherapyAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · completed · Tuberculosis · study chair
- Ph2NCT01392911 · Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TBRadboud University Medical Center · completed · Pulmonary Tuberculosis (TB) · principal investigator
- Ph2NCT01218217 · Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TBMichael Hoelscher · completed · Tuberculosis, Pulmonary · principal investigator
- Ph2NCT01215851 · Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)Global Alliance for TB Drug Development · completed · Pulmonary Tuberculosis · principal investigator
- Ph2NCT01215110 · Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)Global Alliance for TB Drug Development · completed · Pulmonary Tuberculosis · principal investigator
- Ph2NCT00944021 · Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)Global Alliance for TB Drug Development · completed · Pulmonary Tuberculosis · principal investigator
- Ph3NCT00864383 · Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary TuberculosisGlobal Alliance for TB Drug Development · completed · Pulmonary Tuberculosis · principal investigator
- Ph2NCT00567840 · PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary TuberculosisGlobal Alliance for TB Drug Development · completed · Pulmonary Tuberculosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Daniel R. Kuritzkes · fiscal years 2006 to 2010Named on NCT01589497
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:38 UTC. The ranking covers the 200 most relevant of 84 PubMed records, and a shared surname and initials can bring in a namesake. All 84 on PubMed
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.N Engl J Med · 2020771 citationsRCR 48.7
- The diarylquinoline TMC207 for multidrug-resistant tuberculosis.N Engl J Med · 2009634 citationsRCR 18.7
- Multidrug-resistant tuberculosis and culture conversion with bedaquiline.N Engl J Med · 2014581 citationsRCR 21.8
- Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.N Engl J Med · 2019469 citationsRCR 19.7
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.Lancet · 2012350 citationsRCR 11.9
- Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.N Engl J Med · 2018329 citationsRCR 13.1
- High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.Lancet Infect Dis · 2017304 citationsRCR 13.7
- Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.Antimicrob Agents Chemother · 2012295 citationsRCR 10.3
- A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.Am J Respir Crit Care Med · 2015264 citationsRCR 10.9
- Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.Eur Respir J · 2016253 citationsRCR 10.9